• Lantern Pharma priced a concurrent private placement of unregistered warrants to buy up to 3,669,725 common shares.
• Warrants carry a $1.09 exercise price, exercisable only after stockholder approval, with a five-year term from approval.
• Potential gross proceeds total about $4 million if the warrants are fully exercised for cash, with no assurance of exercise.
• Closing is expected around Sept. 30, 2026, alongside a $4 million registered direct offering priced at $1.09 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609290800BIZWIRE_USPR_____20260929_BW092244) on September 29, 2026, and is solely responsible for the information contained therein.